Gilead Sciences Reports Phase 3 PURPOSE 1 Results for Lenacapavir in HIV Prevention

Gilead Sciences today announced results from the Phase 3 PURPOSE 1 trial evaluating twice-yearly subcutaneous lenacapavir for HIV prevention in cisgender women and adolescent girls in sub-Saharan Africa. The trial demonstrated 100% efficacy of lenacapavir in preventing HIV infection, with zero HIV infections in the lenacapavir arm compared to infections in the background incidence group. These results represent a potential paradigm shift in HIV prevention.